Zydus Lifesciences Ltd

Zydus Lifesciences Ltd

₹ 1,079 -0.02%
19 Jun 10:38 a.m.
About

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.
Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe

Key Points

One of the top five pharmaceutical companies in India.[1]

  • Market Cap 1,08,548 Cr.
  • Current Price 1,079
  • High / Low 1,172 / 548
  • Stock P/E 31.5
  • Book Value 156
  • Dividend Yield 0.27 %
  • ROCE 23.0 %
  • ROE 23.5 %
  • Face Value 1.00

Pros

  • Company has delivered good profit growth of 19.6% CAGR over last 5 years
  • Company has been maintaining a healthy dividend payout of 26.1%

Cons

  • Company has high debtors of 160 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
2,008 2,123 2,009 1,830 1,977 1,981 2,262 2,013 2,579 2,956 2,159 2,371 3,332
1,415 1,506 1,525 1,472 1,519 1,437 1,583 1,554 1,807 1,815 1,510 1,672 1,763
Operating Profit 594 618 484 359 458 544 679 459 772 1,141 649 699 1,569
OPM % 30% 29% 24% 20% 23% 27% 30% 23% 30% 39% 30% 29% 47%
-16 30 -250 26 54 52 109 136 47 82 534 107 352
Interest 20 44 24 25 42 41 64 88 85 90 91 104 106
Depreciation 115 117 119 120 123 123 124 122 120 121 125 128 131
Profit before tax 442 486 91 240 346 432 600 385 615 1,012 968 574 1,685
Tax % -5% 18% 85% 18% 29% 23% 25% 34% 20% 23% 17% 22% 17%
465 400 14 197 247 332 451 256 491 781 805 450 1,405
EPS in Rs 4.54 3.91 0.14 1.92 2.41 3.24 4.46 2.53 4.85 7.71 7.95 4.45 13.96
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
3,527 4,042 5,284 7,032 3,231 5,810 6,037 6,347 7,780 7,837 8,732 10,819
2,820 3,232 3,750 4,454 2,909 4,164 4,400 4,916 5,468 5,916 6,277 6,760
Operating Profit 708 810 1,535 2,578 322 1,646 1,637 1,432 2,312 1,921 2,454 4,059
OPM % 20% 20% 29% 37% 10% 28% 27% 23% 30% 25% 28% 38%
51 305 184 174 582 208 598 848 -102 -144 345 1,076
Interest 111 42 43 26 11 64 90 234 71 135 278 391
Depreciation 117 127 212 221 251 293 358 429 451 479 489 504
Profit before tax 531 946 1,465 2,504 642 1,497 1,787 1,617 1,688 1,164 2,032 4,240
Tax % 6% 4% 13% 19% -3% 27% 17% 13% 13% 26% 25% 19%
499 904 1,271 2,038 662 1,091 1,486 1,413 1,476 858 1,529 3,442
EPS in Rs 4.87 8.83 12.42 19.90 6.47 10.66 14.51 13.80 14.42 8.38 15.11 34.20
Dividend Payout % 31% 20% 19% 16% 50% 33% 24% 25% 24% 30% 40% 9%
Compounded Sales Growth
10 Years: 10%
5 Years: 12%
3 Years: 12%
TTM: 24%
Compounded Profit Growth
10 Years: 14%
5 Years: 20%
3 Years: 28%
TTM: 113%
Stock Price CAGR
10 Years: 18%
5 Years: 36%
3 Years: 20%
1 Year: 94%
Return on Equity
10 Years: 17%
5 Years: 15%
3 Years: 15%
Last Year: 23%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 102 102 102 102 102 102 102 102 102 102 101 101
Reserves 2,809 3,528 4,423 6,174 6,516 7,643 8,467 11,158 12,642 13,138 13,538 15,616
1,786 1,586 1,450 1,223 2,940 2,872 3,583 3,695 3,920 2,665 4,825 6,178
855 1,027 1,362 1,424 1,489 1,546 1,519 1,597 1,799 1,835 2,099 2,190
Total Liabilities 5,552 6,243 7,337 8,923 11,047 12,164 13,671 16,552 18,464 17,740 20,564 24,085
1,497 1,564 1,768 2,155 2,352 2,680 3,932 4,109 4,112 4,336 4,184 4,377
CWIP 464 531 367 297 678 659 675 553 570 384 739 627
Investments 1,280 1,558 2,209 2,318 3,924 3,618 4,195 6,404 6,471 5,118 4,879 7,283
2,311 2,591 2,993 4,154 4,093 5,206 4,868 5,486 7,310 7,902 10,761 11,798
Total Assets 5,552 6,243 7,337 8,923 11,047 12,164 13,671 16,552 18,464 17,740 20,564 24,085

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
445 878 1,084 1,954 867 288 581 1,181 2,227 1,272 1,078 1,999
-709 -408 -577 -1,016 -2,480 28 -713 55 -2,714 586 -1,960 -1,831
250 -446 -387 -923 1,366 -149 65 -967 255 -1,710 827 -301
Net Cash Flow -14 25 120 14 -247 167 -67 268 -231 149 -54 -132

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 71 65 73 89 105 79 128 141 89 106 147 160
Inventory Days 169 171 178 127 338 284 288 261 276 245 205 195
Days Payable 104 119 148 174 361 173 137 161 175 135 120 129
Cash Conversion Cycle 136 117 102 42 82 190 279 241 191 216 232 227
Working Capital Days 72 61 53 70 74 118 161 138 205 225 208 188
ROCE % 15% 20% 27% 38% 8% 15% 16% 14% 12% 10% 14%

Shareholding Pattern

Numbers in percentages

11 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
74.88% 74.88% 74.88% 74.88% 74.88% 74.98% 74.98% 74.98% 74.98% 74.98% 74.98% 74.98%
4.65% 4.11% 3.79% 2.53% 2.86% 2.61% 2.52% 3.42% 4.04% 4.85% 4.99% 5.72%
10.50% 11.25% 11.80% 12.83% 11.94% 12.86% 13.61% 13.51% 13.44% 13.01% 12.96% 12.55%
0.07% 0.07% 0.07% 0.08% 0.08% 0.07% 0.07% 0.07% 0.07% 0.07% 0.07% 0.07%
9.90% 9.69% 9.46% 9.69% 10.24% 9.47% 8.81% 8.01% 7.47% 7.07% 6.99% 6.66%
No. of Shareholders 3,31,1553,51,5953,70,9314,08,0174,55,6244,08,2313,70,3963,38,5703,11,7642,97,9533,06,4952,94,324

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls